![]() Start investing in Silverback Therapeutics Inc stocks from India now with. is a biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. 001-39756 81-1489190 (State or othe r jur i s di c ti on. Silverback Therapeutics 7,262 followers 11mo Activation of TLR8 can elicit a robust immune response, critical for mounting productive anti-tumor and anti-viral responses, through a multi-pronged. Buy Silverback Therapeutics Inc Shares from India at 5.87 (0 Commission) today. Price Action: SBTX shares are down 3.13% at $3.40 during the market session on the last check Friday. (E xac t n ame of re gi s tr an t as s p e c i fi e d i n i ts c h ar te r ) D e l aw are.The Company held cash, cash equivalents, restricted cash, and investments of $319.1 million at the end of 2021, which is expected to fund expenses into 2H of 2026. Silverback Therapeutics is a biotech company developing treatments for cancer, fibrosis, and infectious diseases.The Company initiated Phase 1-enabling toxicology studies for SBT8230 in Q1 of 2022.Silverback did not reveal plans for a clinical trial launch but said it is expecting to submit a “Phase I regulatory submission” in Q4 of 2022.Now, the biotech plans to focus on the chronic hepatitis B virus program SBT8230, which remains in preclinical studies.Silverback said it would lay off about 27% of its employees. ![]() Because SBT6290 used the same linker technology to go after a different target, Nectin4, Silverback decided to scrap both.The Company said it is discontinuing SBT6050 and SBT6290 immuno-oncology candidates after a Phase 1/1b study of SBT6050, going after HER2, showing limited anti-tumor activity cytokine-related adverse events.Silverback will continue the advancement of early-stage discovery research.Silverback Therapeutics Inc SBTX undertakes “strategic realignment,” revealing it would drop its two lead cancer programs and lays off more than a quarter of its staff.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |